Genetic Technologies Limited Announces Publication Of Peer-Reviewed Research On geneType's Pancreatic Cancer Risk Assessment Test, showing Test Showed Nearly 50% Improvement In Traditional Clainical Risk Score In Identifying Patients At High Risk
Portfolio Pulse from Benzinga Newsdesk
Genetic Technologies Limited (NASDAQ:GENE) has announced the publication of a peer-reviewed research paper validating geneType's Pancreatic Cancer risk assessment test. The test showed a nearly 50% improvement to the traditional clinical risk score in identifying patients at a high risk of developing pancreatic cancer. The study evaluated close to 380,000 adults aged 40 to 69 years from the UK Biobank.
October 18, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The publication of a peer-reviewed research paper validating Genetic Technologies' geneType Pancreatic Cancer risk assessment test could potentially boost the company's reputation and market position.
The validation of Genetic Technologies' geneType test through a peer-reviewed research paper could potentially increase the company's credibility in the market. This could lead to increased demand for the company's products, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100